Novartis's $12B Avidity Deal Boosts Biotech Stocks and Neuroscience Pipeline
Novartis' CEO indicated that their $12 billion acquisition of Avidity BioSciences could have been twice as large, highlighting the significance of timing in deal-making.
Tag
Novartis
All articles tagged with #novartis
Novartis Nears $12 Billion Deal to Acquire Avidity Biosciences
Novartis is acquiring Avidity Biosciences for about $12 billion to expand its portfolio in rare muscle disorders and strengthen its US presence, with Avidity's early-stage cardiology programs to be spun off into a new company, Spinco.
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Neuroscience Pipeline
Novartis plans to acquire Avidity Biosciences for $12 billion to strengthen its neuroscience pipeline with late-stage RNA therapeutics targeting neuromuscular diseases, including a new platform for muscle-directed delivery of RNA therapies, aiming for product launches before 2030 and increasing its sales growth forecast to 6% CAGR for 2024-2029.
Novartis Approaches $12 Billion Acquisition of Avidity Biosciences
Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.
Novartis to Acquire Avidity Biosciences for $12 Billion in Cash
Novartis is acquiring U.S. biotech firm Avidity Biosciences for about $12 billion in cash, aiming to expand its RNA therapeutics portfolio and boost growth, with the deal expected to close in the first half of 2026 after Avidity spins out some of its business units.
Novartis Nears $10 Billion Deal to Acquire Avidity Biosciences
Novartis is close to acquiring Avidity Biosciences for over $70 per share, in a deal potentially valued at around $6.8 billion, aiming to strengthen its portfolio amid a wave of biotech M&A and upcoming patent expirations.
Novartis' Remibrutinib Gains FDA Approval for Chronic Spontaneous Urticaria
Novartis received FDA approval for Rhapsido (remibrutinib), the first oral BTK inhibitor for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamines, offering a new, fast-acting, and safe treatment option without the need for injections or lab monitoring.
Monte Rosa’s Stock Soars After $5.7B Novartis Deal
Monte Rosa's stock (GLUE) surged following a $5.7 billion deal with Novartis, significantly impacting its market value.
Novartis to Acquire Tourmaline Bio to Strengthen Cardiovascular Pipeline
Novartis plans to acquire Tourmaline Bio for approximately USD 1.4 billion, gaining access to the Phase 3 ready asset pacibekitug, an anti-IL-6 monoclonal antibody targeting systemic inflammation in atherosclerotic cardiovascular disease, which shows promising results in reducing inflammation markers and addresses an unmet need in cardiovascular risk reduction.
Novartis achieves breakthrough in Sjögren’s syndrome with successful Phase III trials
Novartis announced positive results from its Phase III trials of ianalumab, demonstrating significant improvement in disease activity for Sjögren’s disease, potentially making it the first targeted treatment for this autoimmune disorder. The trials showed the drug was well tolerated and could soon be submitted for regulatory approval.
Novartis Gains Approval for First Malaria Drug for Newborns and Infants
Novartis has received Swissmedic approval for Coartem Baby, the first malaria treatment specifically for newborns and young infants, aiming to fill a treatment gap and increase access in malaria-endemic regions, especially in Africa, on a largely not-for-profit basis.
First malaria drug for newborns and infants approved in Africa
Novartis is expected to receive approval within weeks for Coartem Baby, the first malaria treatment specifically formulated for newborns and young infants in Africa, which could significantly improve care for the most vulnerable populations and reduce malaria-related deaths among children under five.
Novartis Gains Approval for First Malaria Treatment for Newborns and Babies
Swiss authorities approved the first malaria treatment specifically for newborns and infants under 11 pounds, Coartem Baby, developed by Medicines for Malaria Venture and Novartis, addressing a critical treatment gap for vulnerable populations.
Novartis' malaria drug approved for infants and newborns
The first malaria treatment specifically approved for babies and very young children has been developed by Novartis and is expected to be rolled out in African countries soon, addressing a critical treatment gap and potentially saving many young lives, especially in regions with high malaria mortality rates.
Novartis's Pluvicto Achieves Promising Results in Prostate Cancer Trials
Novartis announced that its drug Pluvicto showed significant benefits in delaying disease progression in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, based on interim results from the Phase III PSMAddition trial, and plans to submit for regulatory review after presenting the data.